Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of CHOP and lenalidomide compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of monitoring will be done during and after the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial affect my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) clinical trial (NCT01553786). Contact the study team or your healthcare provider for specific answers.

What this study is about